<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cyclandelate, a <z:chebi fb="1" ids="35620">vasodilator</z:chebi>, was administered to 24 patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0000726'>dementia</z:hpo> in these patients was presumed to be due to <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> caused by <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in cerebral vessels after other possible causes were ruled out </plain></SENT>
<SENT sid="2" pm="."><plain>In a double-blind, cross-over study, patients received 200 mg of cyclandelate four times daily for six weeks and a placebo for six weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Six psychological tests, which reflect various aspects of higher cortical ability, were used to evaluate the effect of cyclandelate on the <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Cyclandelate was found to be no more effective than placebo in improving higher cortical function in these <z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> patients </plain></SENT>
</text></document>